BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 3:07:00 PM | Browse: 1229 | Download: 1089
 |
Received |
|
2012-12-13 14:47 |
 |
Peer-Review Started |
|
2012-12-13 15:59 |
 |
To Make the First Decision |
|
2013-03-11 15:15 |
 |
Return for Revision |
|
2013-03-19 17:18 |
 |
Revised |
|
|
 |
Second Decision |
|
2013-07-05 10:33 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2013-07-05 12:11 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-08-09 19:00 |
 |
Publish the Manuscript Online |
|
2013-11-17 20:09 |
Category |
Obstetrics & Gynecology |
Manuscript Type |
Topic Highlights |
Article Title |
Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer
|
Manuscript Source |
Invited Manuscript |
All Author List |
Kurt Van der Speeten, Anthony O Stuart and Paul H Sugarbaker |
Funding Agency and Grant Number |
|
Corresponding Author |
Kurt Van der Speeten, MD, PhD, Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600 Genk, Belgium. kurt.vanderspeeten@zol.be |
Key Words |
Intraperitoneal chemotherapy; Epithelial ovarian cancer; Ifosfamide; Cisplatin; Carboplatin; Taxanes; Pharmacokinetics; Pharmacodynamics |
Core Tip |
Intraperitoneal (IP) chemotherapy is an important adjuvant treatment strategy in patients with advanced epithelial ovarian cancer. Although the clinical benefits have been demonstrated both in phase Ⅱ and Ⅲ trials, the pharmacologic rationale for this treatment strategy needs to be clarified. This manuscript reviews the pharmacokinetic and pharmacodynamic rationale of IP chemotherapy and analyzes the available data. |
Publish Date |
2013-11-17 20:09 |
Citation |
Van der Speeten K, Stuart AO, Sugarbaker PH. Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer. World J Obstet Gynecol 2013; 2(4): 143-152 |
URL |
http://www.wjgnet.com/2218-6220/full/v2/i4/143.htm |
DOI |
http://dx.doi.org/10.5317/wjog.v2.i4.143 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345